GSK PLC Sponsored ADR $GSK Shares Sold by Clean Yield Group

Key Points

• Clean Yield Group reduced its holdings in GSK PLC by 6.5% during the 2nd quarter, now owning 167,388 shares valued at approximately $6.4 million.
• Several institutional investors, including NewEdge Advisors LLC and TD Private Client Wealth LLC, have increased their stakes in GSK, highlighting growing interest in the pharmaceutical company.
• GSK's recent quarterly earnings exceeded expectations, with a reported $1.23 EPS against an estimate of $1.12, reflecting a 1.3% year-over-year revenue growth to $10.64 billion.

Clean Yield Group cut its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 6.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 167,388 shares of the pharmaceutical company's stock after selling 11,726 shares during the period. GSK makes up approximately 1.9% of Clean Yield Group's holdings, making the stock its 10th biggest position. Clean Yield Group's holdings in GSK were worth $6,428,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. NewEdge Advisors LLC raised its holdings in shares of GSK by 8.6% during the first quarter. NewEdge Advisors LLC now owns 90,663 shares of the pharmaceutical company's stock valued at $3,512,000 after acquiring an additional 7,148 shares during the period. Miller Howard Investments Inc. NY raised its holdings in shares of GSK by 0.8% during the 2nd quarter. Miller Howard Investments Inc. NY now owns 1,659,814 shares of the pharmaceutical company's stock valued at $63,737,000 after purchasing an additional 13,023 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of GSK by 201.9% during the 1st quarter. Acadian Asset Management LLC now owns 3,982,324 shares of the pharmaceutical company's stock valued at $154,244,000 after purchasing an additional 2,663,270 shares in the last quarter. TD Private Client Wealth LLC raised its holdings in shares of GSK by 997.5% during the 2nd quarter. TD Private Client Wealth LLC now owns 78,019 shares of the pharmaceutical company's stock valued at $2,996,000 after purchasing an additional 70,910 shares in the last quarter. Finally, Bard Financial Services Inc. raised its holdings in shares of GSK by 10.2% during the 2nd quarter. Bard Financial Services Inc. now owns 134,745 shares of the pharmaceutical company's stock valued at $5,174,000 after purchasing an additional 12,500 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of research analyst reports. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 5th. Six equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, GSK currently has an average rating of "Reduce" and an average target price of $37.38.

GSK Stock Performance

NYSE GSK opened at $39.83 on Monday. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The firm has a market capitalization of $81.03 billion, a price-to-earnings ratio of 18.44, a P/E/G ratio of 1.99 and a beta of 0.53. The company's fifty day moving average is $39.18 and its two-hundred day moving average is $38.56. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $42.63.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.11. The company had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The business's quarterly revenue was up 1.3% on a year-over-year basis. During the same period last year, the business posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities research analysts forecast that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be given a $0.4206 dividend. This represents a $1.68 annualized dividend and a yield of 4.2%. The ex-dividend date is Friday, August 15th. GSK's dividend payout ratio (DPR) is currently 77.78%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.